Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays

Cancer Research

Volumn 59, Issue 4, 1999, Pages 803-806

  Bubendorf, Lukas ^a   Kononen, Juha ^a   Koivisto, Pasi ^b   Schraml, Peter ^c   Moch, Holger ^c   Gasser, Thomas C ^c   Willi, Niels ^c   Mihatsch, Michael J ^c   Sauter, Guido ^c   Kallioniemi, Olli P ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CYCLIN D1;

ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HORMONAL THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTASIS; MOLECULAR GENETICS; MUTATION; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER;

CYCLIN D1; GENE AMPLIFICATION; GENES, ERBB-2; GENES, MYC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 0033557839     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Mettlin, C. Clinical oncology update: prostate cancer. Eur. J. Cancer, 33: 340-347, 1997.
2. Isaacs, J. T. Molecular markers for prostate cancer metastasis: developing diagnostic methods for predicting the aggressiveness of prostate cancer. Am. J. Pathol., 150: 1511-1521, 1997.
3. Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M., Schraml, P., Leignton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., and Kallioniemi, O-P. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med., 4: 844-847, 1998.
4. Fournier, G., Latil, A., Amet, Y., Abalain, J. H., Volant, A., Mangin, P., Floch, H. H., and Lidereau, R. Gene amplifications in advanced-stage human prostate cancer. Urol. Res., 22: 343-347, 1995.
5. Latil, A., Baron, J. C., Cussenot, O., Fournier, G., Boccon, G. L., Le, D. A., and Lidereau, R. Oncogene amplifications in early-stage human prostate carcinomas. Int. J. Cancer, 59: 637-638, 1994.
6. Han, E. K., Lim, J. T., Arber, N., Rubin, M. A., Xing, W. Q., and Weinstein, I. B. Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate, 35: 95-101, 1998.
7. Jenkins, R. B., Qian, J., Lieber, M. M., and Bostwick, D. G. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res., 57: 524-531, 1997.
8. Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinanen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., and Kallioniemi, O-P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet., 9: 401-406, 1995.
9. Koivisto, P., Kononen, J., Palmberg, C., Tammela, T., Hyytinen, E., Isola, J., Trapman, J., Cleutjens, K., Noordzij, A., Visakorpi, T., and Kallioniemi, O-P. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res., 57: 314-319, 1997.
10. Kuhn, E. J., Kurnot, R. A., Sesterhenn, I. A., Chang, E. H., and Moul, J. W. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J. Urol., 150: 1427-1433, 1993.
11. Ross, J. S., Sheehan, C., Hayner, B. A., Ambros, R. A., Kallakury, B. V., Kaufman, R., Fisher, H. A., and Muraca, P. J. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. Hum. Pathol., 28; 827-833, 1997.
12. Ross, J. S., Sheehan, C. E., Hayner, B. A., Ambros, R. A., Kallakury, B. V., Kaufman, R. J., Fisher, H. A., Rifkin, M. D., and Muraca, P. J. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer (Phila.), 79: 2162-2170, 1997.
13. International Union Against Cancer (UICC). Classification of malignant tumours, Ed. 5. New York: Wiley-Liss, 1997.
14. Qian, J., Bostwick, D. G., Takahashi, S., Borell, T. J., Brown, J. A., Lieber, M. M., and Jenkins, R. B. Comparison of fluorescence in situ hybridization analysis of isolated nuclei and routine histological sections from paraffin-embedded prostatic adenocarcinoma specimens. Am. J. Pathol., 149: 1193-1199, 1996.
15. Visakorpi, T., Kallioniemi, A. H., Syvanen, A C., Hyytinen, E. R., Karhu, R., Tammela, T., Isola, J. J., and Kallioniemi, O-P. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res., 55: 342-347, 1995.
16. Cher, M. L., Bova, G. S., Moore, D. H., Small, E. J., Carroll, P. R., Pin, S. S., Epstein, J. I., Isaacs, W. B., and Jensen, R. H. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res., 56: 3091-102, 1996.
17. Alers, J. C., Krijtenburg, P. J., Rosenberg, C., Hop, W. C., Verkerk, A. M., Schroder, F. H., Van der Kwast, T., Bosman, F. T., and van Dekken, H. Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone. Lab. Invest., 77: 437-448, 1997.
18. Kirby, R. S., Christmas, T. J., and Brawer, M. Management of metastatic disease. In: R. S. Kirby, T. J. Christmas, and M. Brawer (eds.), Prostate Cancer, pp. 129-141. London: Mosby, 1996.
19. Nupponen, N. N., Kakkola, L., Koivisto, P., and Visakorpi, T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am. J. Pathol., 153: 141-148, 1998.